Systematic evaluation of non-animal test methods for skin sensitisation safety assessment  by Reisinger, Kerstin et al.
Toxicology in Vitro 29 (2015) 259–270Contents lists available at ScienceDirect
Toxicology in Vitro
journal homepage: www.elsevier .com/locate / toxinvi tSystematic evaluation of non-animal test methods for skin sensitisation
safety assessmenthttp://dx.doi.org/10.1016/j.tiv.2014.10.018
0887-2333/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author. Tel.: +49 211 7972979; fax: +49 211 7977887.
E-mail addresses: kerstin.reisinger@henkel.com (K. Reisinger), sebastian.hoffmann@seh-cs.com (S. Hoffmann), nalepee@rd.loreal.com (N. Alépée), takao.ashi
shiseido.co.jp (T. Ashikaga), Joao.BARROSO@ec.europa.eu (J. Barroso), CliffElcombe@cxrbiosciences.com (C. Elcombe), Nichola.Gellatly@unilever.com (N. Gellatly), v
galbiati@unimi.it (V. Galbiati), S.Gibbs@vumc.nl (S. Gibbs), hgroux@immunosearch.fr (H. Groux), jalila.hibatallah@chanel-corp.com (J. Hibatallah), dkeller@cee
(D. Keller), kern.ps@pg.com (P. Kern), mklaric@cosmeticseurope.eu (M. Klaric), susanne.kolle@basf.com (S. Kolle), jochen.kuehnl@beiersdorf.com (J.
nathalie.lambrechts@vito.be (N. Lambrechts), malin.lindstedt@immun.lth.se (M. Lindstedt), marion.millet@pierre-fabre.com (M. Millet), steissier@rd.lo
(S. Martinozzi-Teissier), andreas.natsch@givaudan.com (A. Natsch), ian.pike@proteomics.com (I. Pike), sakaguchi.hitoshi@kao.co.jp (H. Sakaguchi), andreas.s
beiersdorf.com (A. Schepky), mtailhardat@research.lvmh-pc.com (M. Tailhardat), marie.templier@pierre-fabre.com (M. Templier), erwin.vanvliet@secam-ce.eu (E. v
Gavin.Maxwell@unilever.com (G. Maxwell).
1 Contributed equally.
2 Members of the Cosmetics Europe Skin Tolerance Task Force, Cosmetics Europe, Avenue Herrmann Debroux 40, B-1160 Auderghem, Brussels, Belgium.
3 Current address: European Commission, DG Joint Research Centre (JRC), Institute for Health and Consumer Protection (IHCP), via Enrico Fermi 2749, 21027 Ispra (VKerstin Reisinger a,1,2,⇑, Sebastian Hoffmann b,1,2, Nathalie Alépée c,2, Takao Ashikaga d,2, Joao Barroso e,2,3,
Cliff Elcombe f, Nicola Gellatly g,2, Valentina Galbiati h, Susan Gibbs i, Hervé Groux j, Jalila Hibatallah k,2,
Donald Keller l, Petra Kernm,2, Martina Klaric e,2, Susanne Kolle n, Jochen Kuehnl o, Nathalie Lambrechts p,
Malin Lindstedt q, Marion Millet r,2, Silvia Martinozzi-Teissier c,2, Andreas Natsch s, Dirk Petersohn a,2,
Ian Pike t, Hitoshi Sakaguchi u,2, Andreas Schepky o,2, Magalie Tailhardat v,2, Marie Templier r,2,
Erwin van Vliet w,2, Gavin Maxwell g,2
aHenkel AG & CO KGaA, Henkelstr. 67, 40191 Düsseldorf, Germany
b Seh Consulting + Services, Rathausplatz 9, 33098 Paderborn, Germany
c L’Oréal Research & Innovation, 1, Avenue Eugene Schueller, 93600 Aulnay sous bois, France
d Shiseido Co, Ltd, Quality Assurance Center, Kanagawa, Japan
eCosmetics Europe, Avenue Herrmann Debroux 40, B-1160 Auderghem, Brussels, Belgium
fCXR Biosciences Ltd., 2 James Lindsay Place, Dundee Technopole, Dundee DD1 5JJ, UK
gUnilever, Safety and Environmental Assurance Centre, Sharnbrook, Bedford MK44 1LQ, UK
h Laboratory of Toxicology, University Milan, Via Balzaretti 9, 20133 Milan, Italy
iVU University Medical Centre, Department Dermatology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
j ImmunoSearch, Les Cyclades, Chemin de Camperousse, 06130 Le plan de Grasse, France
kChanel, 135 Avenue Charles de Gaulle, 92521 Neuilly sur Seine, France
lCyprotex, LLC, 4717 Campus Drive, Kalamazoo, MI, USA
m Procter & Gamble Technology (Beijing) Co., Ltd., Global Product Stewardship, No. 35 Yu An Road, KongGang Development Area (Area B), Shunyi District, Beijing 101312, PR China
nBASF SE, Experimental Toxicology and Ecology, 67056 Ludwigshafen, Germany
oBeiersdorf AG, Unnastrasse 48, 20245 Hamburg, Germany
pVITO NV, Industriezone Vlasmeer 7, 2400 Mol, Belgium
qDepartment of Immunotechnology, Lund University, Medicon Village (406), 22381 Lund, Sweden
r Institut de Recherche Pierre Fabre, CEPC – Bel air de Campans, 81106 Castres Cedex, France
sGivaudan Schweiz AG, Ueberlandstrasse 138, 8600 Dübendorf, Switzerland
t Proteome Sciences plc, Coveham House, Downside Bridge Road, Cobham KT11 3EP, UK
uKao Corporation, Safety Science Research Laboratories, Ichikai-Machi, Haga-Gun, Tochigi, Japan
v LVMH Recherche, 185 avenue de Verdun, 45804 St Jean de Braye Cedex, France
w Services & Consultation on Alternative Methods (SeCAM), Via Fontanone 27, 6982 Agno, Switzerland
a r t i c l e i n f oArticle history:
Received 27 March 2014
Accepted 21 October 2014
Available online 31 October 2014a b s t r a c t
The need for non-animal data to assess skin sensitisation properties of substances, especially cosmetics
ingredients, has spawned the development of many in vitro methods. As it is widely believed that no
single method can provide a solution, the Cosmetics Europe Skin Tolerance Task Force has deﬁned a
three-phase framework for the development of a non-animal testing strategy for skin sensitisationkaga@to.
alentina.
tox.com
Kuehnl),
real.com
chepky@
an Vliet),
A), Italy.
260 Reisinger and Hoffmann et al. / Toxicology in Vitro 29 (2015) 259–270Keywords:
Skin sensitisation
Testing strategy
Safety assessment
Non-animal test methods
Adverse Outcome Pathwayspotency prediction. The results of the ﬁrst phase – systematic evaluation of 16 test methods – are pre-
sented here. This evaluation involved generation of data on a common set of ten substances in all meth-
ods and systematic collation of information including the level of standardisation, existing test data,
potential for throughput, transferability and accessibility in cooperation with the test method developers.
A workshop was held with the test method developers to review the outcome of this evaluation and to
discuss the results. The evaluation informed the prioritisation of test methods for the next phase of the
non-animal testing strategy development framework. Ultimately, the testing strategy – combined with
bioavailability and skin metabolism data and exposure consideration – is envisaged to allow establish-
ment of a data integration approach for skin sensitisation safety assessment of cosmetic ingredients.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The mechanism behind skin sensitisation and the elicitation of
Allergic Contact Dermatitis (ACD) has been investigated for many
years and is documented by the OECD as an Adverse Outcome Path-
way (AOP) (OECD, 2012). The skin sensitisation AOP captures the
impact of skin exposure to sensitising chemicals as a series of bio-
logical and chemical key events, which have been reviewed exten-
sively, e.g. by Ainscough et al. (2013), Kimber et al. (2012), Martin
et al. (2011), and Toebak et al. (2009). In brief, as a prerequisite,
the chemical sensitizer needs to penetrate the stratum corneum
as the uppermost layer of the skin in order to become available to
the viable cells of the epidermis. It binds covalently to skin proteins
of the viable cells (key event 1) to form hapten-protein conjugates,
which can be immunogenic. In parallel, keratinocytes become acti-
vated and release danger signals e.g. pro-inﬂammatory cytokines as
a response to trauma (key event 2). Next, the phenotype of dendritic
cells (DC) changes by the concerted recognition of hapten-protein
conjugates by MHC (major histocompatibility complex) molecules
and of danger signals (key event 3). The activated DCs mobilise
andmigrate, after maturational changes, from the skin to the drain-
ing lymph node to present the allergen to T cells. After binding to a
hapten-peptide speciﬁc T cell this clonewill expand (key event 4) to
elicit the eventual adverse outcome in case of a second exposure
with the chemical sensitiser. This level of mechanistic understand-
ing has enabled the development of a multitude of non-animal test
methods that each aim to measure the impact of substances on one
or more of the AOP key events and therefore to distinguish sensitis-
ers from non-sensitisers or to generate potency information
(reviewed previously in Adler et al. (2011)). The complexity of the
underlying biology has resulted in the hypothesis that no single
measurement will be sufﬁcient to predict sensitiser potency alone
(Jowsey et al., 2006). Consequently efforts to apply data from these
non-animal test methods for hazard characterisation or risk
assessment have focussed upon integration of multiple data types
(for example, MacKay et al., 2013; Jaworska et al., 2011; Bauch
et al., 2012; Nukada et al., 2012; Natsch et al., 2013). Whilst these
approaches continue to show promise, the majority have focused
upon integrating non-animal data to predict sensitiser potential.
Consequently, one major objective of the Cosmetics Europe Skin
Tolerance Task Force has been to identify and evaluate testmethods
that could allow sensitiser potency prediction without the need for
new animal test data, which is of vital importance for the cosmetics
industry (Maxwell et al., 2011). This evaluation will inform the
development of a non-animal testing strategy for skin sensitisation
potency predictions. The resulting strategy will ultimately become
an essential part – along with consideration of exposure and other
information such as bioavailability or metabolism – of a data
integration approach for the skin sensitisation safety assessment
of cosmetic ingredients.
Here we document the ﬁrst of three phases to develop such a
non-animal testing strategy. Sixteen test methods were identiﬁedfor systematic evaluation, following a review of the available scien-
tiﬁc literature. The aim of this evaluation was to gain comparable
detailed understanding of the test methods that would allow
promising methods to be prioritised for further in-depth evalua-
tion. Therefore, a common set of criteria was assessed involving
test method characterisation and standardisation. Such criteria
included AOP mapping, ease of transferability, availability and
throughput, performance (in terms of reproducibility and predic-
tivity) as well as legal aspects and information. The information
was assembled for each test method in collaboration with the
developers. In addition, we have compiled data on a set of ten
substances for each of the methods to verify publically available
data in terms of both sensitiser potential and potency prediction.
The resulting analysis forms a comprehensive review of the results
obtained, which informed the selection of test methods for the
next evaluation phases. Finally, we present our future framework
set-up for the development of a non-animal testing strategy for
skin sensitisation potency predictions – a data and knowledge
gap identiﬁed by a previous review of non-animal risk assessment
approaches for skin sensitisation (Goebel et al., 2012).
2. Material and methods
2.1. Description of test methods
The following section provides an overview of the 16 test meth-
ods, which were analysed during the ﬁrst phase of the Cosmetics
Europe method evaluation process. They are presented according
to their alignment to the skin sensitisation AOP (Fig. 1). The descrip-
tion,which covers the status at the beginning of 2013, comprises the
test system, read-out parameter, predictionmodel, andwhether the
method provides only hazard identiﬁcation or also includes potency
prediction. Finally, the experimental conditions are summarised
(including the applied dose range) as this may indicate whether
the data obtained have the potential to add information to hazard
characterisation beyond the currently used prediction model. As
detailed information about each of the test methods is already
available in the scientiﬁc literature, this is not covered here. The lab-
oratories in which the methods have been developed are indicated
and key references are included for further reading.
2.1.1. Protein reactivity test methods
Skin sensitisers show a high diversity in terms of chemical and
physiochemical properties. However the AOP considers, chemicals
– or in case of pre-/pro-haptens, their respective metabolites –
which act as sensitisers due to their ability to react with skin
proteins (haptenation). This common characteristic is used in a
number of non-animal test methods to differentiate between
sensitisers and non-sensitisers. Two in chemico assays focus on pep-
tide reactivity using two model peptides as surrogates for cellular
proteins. In addition, three cell line assays use the kelch-like
ECH-associated protein 1 (Keap1) as an intracellular sensor to
Fig. 1. Non-animal test methods and their alignment to the skin sensitisation AOP. Test methods analysed during of phase I of the Cosmetics Europe method evaluation study
(grey boxes). Methods presented in white boxes represent Cosmetics Europe-funded studies to cover the steps in the AOP, which are currently not represented by a non-
animal assay.
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to cysteine residues of Keap 1 causes this repressor protein to
delocalize from the transcription factor NF-E2 p45-related factor
2 (Nrf2) which can then bind to and activate antioxidant response
element (ARE) containing promoters.
Whilst all ﬁve protein reactivity methods reﬂect the well estab-
lished importance of interaction between electrophilic haptens and
nucleophilic target proteins, the cell line based assays address in
addition the induction of cytoprotective mechanisms (referring to
AOP key event 2). KeratinoSens™ and LuSens furthermore provide
the potential for keratinocyte metabolism of pro-haptens.
2.1.1.1. Direct peptide reactivity assay (DPRA, Procter & Gamble)
The DPRA is a chemistry-based assay that evaluates reactivity of
a test compound using two synthetic model peptides including a
lysine or cysteine residue. A solution of peptide and test substance
in a ratio of 1:10 for cysteine and 1:50 for lysine is incubated for
24 h. After the incubation period, the remaining concentration of
the free peptide is measured by high performance liquid
chromatography (HPLC) with gradient elution and ultraviolet
(UV) detection at 220 nm. Depending on the data obtained from
triplicate reactions, averaged peptide depletion of cysteine, lysine
or both are used in classiﬁcation tree models to identify substances
as sensitising or non-sensitising. In addition, the prediction model
allows the allocation of the protein to the reactivity classes
minimal, low, moderate and high (Gerberick et al., 2004, 2007).
2.1.1.2. Peroxidase peptide reactivity assay (PPRA, Procter & Gamble)
The PPRA was developed from the DPRA in order to better iden-
tify potential pro- and pre-haptens. Eight concentrations of chem-
ical are tested – instead of one concentration as in the DPRA. The
cysteine peptide is incubated for 24 h in the presence and absence
of horseradish peroxidase/hydrogen peroxide (HRP/P), whilst the
lysine peptide is used only without HRP/P. Following incubation,
all concentrations are processed for analysis by HPLC/mass spec-trometry (MS)/MS (maximum concentrations of test compound:
5 mM for cysteine, 25 mM for lysine). From the concentration–
response peptide depletion data the effective concentration of a
test substance that depletes peptides by 25% (i.e., EC25) is esti-
mated by ﬁtting a three-parameter log–logistic model. Substances
with an EC25P 0.1 mM are considered ‘reactive’ and those with an
EC25 < 0.1 mM are considered ‘highly reactive’. Both are therefore
classiﬁed as ‘sensitisers’, while substances with less than 15.1%
depletion at any concentration are considered ‘minimally reactive’
and classiﬁed as ‘non-sensitisers’ (Gerberick et al., 2009).
2.1.1.3. AREc32 cell line assay (CXR Bioscience)
The AREc32 cell line assay was the ﬁrst method exploiting the
activation of the Keap1/Nrf2/ARE pathway using a breast cancer
cell line (MCF-7), which contains a luciferase gene construct con-
trolled by eight copies of the ARE cis-enhancer element (Wang
et al., 2006). The cytotoxicity of the substances is investigated in
parallel by measuring adenosine triphosphate (ATP) levels. Lucifer-
ase expression at 50% above the vehicle control value is selected as
representative of signiﬁcant induction in any of the applied seven
concentrations (max. 100 lM). Hence, test items that induce lucif-
erase expression above this threshold are considered as potential
sensitising. More recently, Natsch and Emter proposed to replace
the intracellular ATP measurement by the MTT assay (Natsch and
Emter, 2008).
2.1.1.4. KeratinoSens™ (Givaudan)
Using the metabolic-competent human keratinocyte HaCaT cell
line, the developers of the KeratinoSens™ test method transferred
a stable insertion of a luciferase gene under the control of the ARE-
element of the human gene AKR1C2, which has been shown to be a
key sensitiser-induced gene. These cells are exposed to 12 concen-
trations of a test substance (max. 2000 mM) for 48 h. Luciferase
induction and cytotoxicity as determined with the MTT assay are
then evaluated. For luciferase expression the maximal fold-induc-
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reach a 1.5-fold induction (EC1.5) are calculated. For cytotoxicity
the IC50, i.e. the concentration inducing 50% of the maximum cyto-
toxicity, value is derived. A test substance is being identiﬁed as
sensitiser if the Imax shows a >1.5-fold gene induction, this induc-
tion is statistically signiﬁcant above the solvent control value and
the EC1.5 value is below 1000 lM in at least two of three repeti-
tions. In addition, at EC1.5, cellular viability needs to be above
70% (Emter et al., 2010; Natsch et al., 2011).
2.1.1.5. LuSens (BASF)
The LuSens assay uses a keratinocyte-derived cell line, to which
a luciferase gene under the control of an ARE promoter (from the
NADPH:quinone oxidoreductase 1 rat gene) was inserted (Bauch
et al., 2012). In a range ﬁnding experiment the cytotoxicity of 12
test substance concentrations is evaluated by determination of a
CV75 using the MTT assay. In the main experiments, a minimum
of six concentrations are applied, up to a maximum of
1.2  CV75 of the range ﬁnding experiment. For non-toxic sub-
stances the maximum concentration (2000 lM) is selected to start
the concentration range. Luciferase activity and cytotoxicity is
measured after 48 h of treatment. A test substance is considered
to exhibit a keratinocyte activating potential if the luciferase activ-
ity exceeds 1.5-fold induction with respect to the vehicle control,
at a concentration that does not reduce a viability to below 70%.
2.1.2. Keratinocyte based test methods associated to inﬂammatory-
related read-outs
Keratinocytes are relevant to the manifestation of inﬂammatory
effects in the skin in response to haptens, which is important for
the activation of hapten-presenting dendritic cells (DC) and for
inducing their migration to adjacent lymph nodes. There is grow-
ing evidence that the induction of the innate immune system by
so-called ‘danger signals’ is mediated by the same pathways as ﬁrst
described for microbial pathogens (Martin et al., 2011). Danger
signals created by pathogen invasion or chemical penetration
through the stratum corneum activate keratinocytes to produce
inﬂammatory mediators, such as IL-18 and IL-1b, which in turn
activate DCs during the sensitisation process. These processes
relate to key event 2 in the skin sensitisation AOP.
2.1.2.1. NCTC 2544 IL-18 assay (Università degli Studi di Milano)
The NCTC 2544 assay is based on the detection of intracellular
IL-18 expression by the keratinocyte cell line NCTC 2544. In a dose
range-ﬁnding experiment, 12 concentrations are used to deter-
mine the concentration resulting in a cell viability of 80% (CV80),
as assessed by the MTT assay. The CV80 then deﬁnes the highest
of four concentrations used in the main experiment. If at least
one non-cytotoxic concentration induces a 1.2-fold increase in
intracellular IL-18, and this increase in IL-18 is statistically
signiﬁcant compared to vehicle treated cells (Dunnett multiple
comparisons test), in at least two out of three independent
experiments, the substance is classiﬁed as a sensitiser. Otherwise
it is considered non-sensitising (Corsini et al., 2009; Galbiati
et al., 2011).
2.1.2.2. Epidermal equivalent (EE) potency assay (VU University
medical Centre)
The epidermal equivalent (EE) potency assay aims to classify
sensitiser potency using epidermal equivalents, which requires
prior identiﬁcation of a substance as a sensitiser. In the literature,
the NCTC 2544 IL-18 assay has been used to provide this informa-
tion. Substances (spread on ﬁlter papers) are topically applied to
the EE at a range of 12 concentrations for 24 h. The effective chem-
ical concentration required to reduce cell viability by 50% relative
to vehicle-exposed culture (EE-EC50) is calculated using the MTTassay. The EE-EC50 are then assigned to a potency category using
a prediction model correlating previous results with local lymph
node assay (LLNA) data (dos Santos et al., 2011; Gibbs et al., 2013).
2.1.3. Test methods using dermal dendritic cell surrogates
The following ﬁve assays use primary cells or cell lines as surro-
gates fordermalDC.Proteinexpressionof cell surfacemarkerswhich
are considered prerequisites for the migration of dermal DC to the
adjacent lymph nodes (key event 3 in the skin sensitisation AOP)
such as CD54 and/or CD86 or gene expression of e.g. chemokine
receptor (CCR)2 are used as measurements of cell activation.
2.1.3.1. Human cell line activation test (h-CLAT, Kao and Shiseido)
The h-CLAT assay uses THP-1 cells (a human monocytic leuke-
mia cell line) as a surrogate for dermal dendritic cells. The THP-1
cells are treated with eight different concentrations of a test sub-
stance for 24 h. After removing the test substance, expression of
CD86 and CD54 is measured by ﬂow cytometry. Relative
ﬂuorescence intensity (RFI) compared to vehicle-only treated
control cells is used as an indicator of CD86 and CD54 induction.
A test substance is considered a skin sensitiser in case the RFI of
either CD86 or CD54 reaches deﬁned thresholds (CD86P 150%
and/or CD54P 200%), in at least two of three independent
measurements at any concentration. Concentrations exceeding
50% cytotoxicity, measured with propidium iodide (PI), are
excluded from analysis (Ashikaga et al., 2010).
2.1.3.2. Myeloid U937 skin sensitisation test (MUSST, L‘Oréal)
The MUSST assay, which uses the U937 cell line (a human his-
tiocytic leukemia cell line) is designed to evaluate the capacity of a
substance to induce dendritic cell activation. To achieve this, CD86
expression is assessed by ﬂow cytometry, following a 45 h incuba-
tion with the test substance in at least four different concentra-
tions up to a maximum of 200 lg/mL. Concentrations exceeding
30% cytotoxicity, measured with PI, are excluded from analysis. A
substance inducing an increase in CD86 protein expression of
P150% with evidence of a dose response in at least two concordant
experiments is considered to be a sensitiser. If the CD86 positive
threshold is not reached and no perturbations are observed in at
least two concordant experiments, the substance is considered to
be a non-sensitiser. In the other cases, rules based on CD86
expression or cell viabilities are used in order to classify the chem-
ical as sensitising or non-sensitising (Ade et al., 2006).
2.1.3.3. Modiﬁed myeloid U937 skin sensitisation test (mMUSST, BASF)
The mMUSST also uses the U937 cell line measuring CD86 by
ﬂow cytometry. Five concentrations, chosen based on preliminary
PI cytotoxicity assays, are applied for 48 h. The highest tested con-
centration in the main experiment is two times the concentration
causing a cytotoxicity of 25% (CV75). A test substance is predicted
to have a dendritic cell line activating potential when CD86 induc-
tion exceeds the threshold of 1.2 with respect to vehicle treated
cells at any tested concentration showing sufﬁcient cell viability
(P70%) in at least two independent experiments (Bauch et al.,
2012).
2.1.3.4. Peripheral blood monocyte-derived dendritic cell assay
(PBMDC, Beiersdorf)
In contrast to the above cell line-based assays, the PBMDC assay
uses human peripheral blood monocyte-derived dendritic cells iso-
lated from the fresh buffy coats of ﬁve different donors. CD1a neg-
ative/CD14 positive monocytes are selected and differentiated by
culturing with GM-CSF and IL-4. Cells are then exposed to at least
six concentrations of the test substance. The second highest con-
centration should correspond to a viability of at least 80%. Non-
cytoxic substances are applied up to 1000 lM or the highest solu-
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is determined by ﬂow cytometry. Dead cells are detected using 7-
Aminoactinomycin (7-AAD) staining. If a test substance induces on
average P20% increase in CD86-positive cells compared to non-
treated cells it is considered as a skin sensitiser. The acceptable rel-
ative cytotoxicity range is limited to 620% (Reuter et al., 2011).
2.1.3.5. VITOSENS (VITO)
The VITOSENS assay uses differentiated CD34+ progenitor cells
derived from human cord blood as surrogate for DC. The response
to test substance exposure is evaluated by comparing the fold
change in the expression of CCR2 (C–C chemokine receptor type
2) and the transcription factor cAMP responsive element modula-
tor (CREM) compared to solvent-exposed cells (Hooyberghs et al.,
2008). In a concentration range-ﬁnding experiment using cells
from one donor, the concentration that yields around 20% cell
death (IC20) at 24 h is determined using PI staining and ﬂow
cytometry. Next, the cells are exposed to a dilution series including
the IC20 concentration or, in case of a non-cytotoxic substance,
with the highest soluble concentration. After 6 h, 0.5 million cells
are collected for later RNA extraction and subsequent qPCR of
CREM and CCR2 to analyse their relative gene expression. After
24 h, the remainder of the cells is collected and the cell viability
is determined using PI. The concentration that is then conﬁrmed
to induce 20% cell death in all donors is used for the molecular
analysis and prediction of the sensitisation outcome. The experi-
mental set-up is repeated on cell cultures from two different cord
blood donors. In case of discordant results, a third donor is tested.
The resulting fold changes are combined by a weighted average to
predict whether the substance is sensitising or non-sensitising.
Furthermore, the fold changes of CREM and CCR2 can be combined
with the IC20-value in a tiered approach for potency prediction (is
Lambrechts et al., 2010, 2011).
2.1.4. Other test methods
The methods described previously use one or two read-out
parameters to provide information on the sensitising potential or
potency of a test compound. The following methods were allocated
to this section as they investigate a set of 10–200 parameters and so
may have the ability to provide further insight into the mechanism
by which a speciﬁc compound induces skin sensitisation. Note that
both GARD and SensiDerm™ use surrogates of dendritic cells (see
Section 2.1.3) and Sens-IS and SenCeeTox expose 3D epidermal skin
tissues addressing substance activation by keratinocytes as well as
the cytotoxicity of a substance (see Sections 2.1.1 and 2.1.2).
2.1.4.1. Sens-IS (Immunosearch)
The Sens-IS method classiﬁes sensitisers according to potency
categories based on the expression proﬁles of 65 genes, which
are grouped in one gene set for irritancy and two (SENS-IS and
ARE) for sensitisation (Cottrez, 2011). EpiSkin tissues (Skinethic,
France) are exposed with the test substances using the protocol
for determining in vitro skin irritation described in OECD Guideline
439 (15 min incubation, then washing and post-washing incuba-
tion of 6 h). A test substance is considered to be sensitiser if it
increases the expression (compared to the solvent control) of at
least 7 genes measured by qPCR in either the ‘‘SENS-IS’’ or the
‘‘ARE’’ gene sets. To take into account non-speciﬁc gene over-
expression due to cell stress, the induction of more than 20 genes
in the irritation gene set, classiﬁes a result as inconclusive and the
test substance is re-analysed at a lower concentration. Similarly to
the LLNA, potency is classiﬁed according to the concentration of
test material needed to induce a positive response: positive at
0.1%: extreme; positive at 1%: strong; positive at 10%: moderate;
positive at 50%: weak. Sens-IS is considered to mainly address
key event 2 from the skin sensitisation AOP, but may, as ARE-acti-vated genes are included, also provide information on protein reac-
tivity of a test chemical.
2.1.4.2. SenCeeTox (Cyprotex, LLC)
The SenCeeTox method is a test battery of three independent
assays addressing several key events to provide information on
the skin sensitisation potential of substances and to assign them
to a certain subset of potency categories (McKim et al., 2012). Pro-
tein reactivity is evaluated in a cell-free manner by measurement of
the concentration of free glutathione (GSH) after incubation with
the test substance for 24 h at room temperature. The amount of free
GSH is determined by a colorimetric assay with 5,50-Dithio-bis(2-
nitrobenzoic acid (DTNB) in relation to the vehicle control. An epi-
dermal skin equivalent (EpiDerm™, MatTek, MA) is used for gene
expression analysis and cytotoxicity determination. Viability of skin
tissues is measured by assaying for lactose dehydrogenase (LDH)
activity. Expression of four housekeeping and seven target genes
(NADPH-quinone oxidoreductase 1, Aldoketoreductase 1C2, Inter-
leukin 8, Cytochrome P450 1A1, Aldehyde dehydrogenase 3A,
Heme-oxygenase 1, Glutamate cysteine ligase catalytic subunit C)
is monitored after topical exposure of the model skin tissues to
the test substances at a range of six concentrations (0.1, 5, 100,
250, 500, and 2500 lM) for 24 h. Concentrations, which result in cell
viability of less than 50% compared to the vehicle control, are disre-
garded for the determination of the sensitising potential/potency.
Finally, a gated algorithm is used to transform the viability, gene
induction and glutathione reactivity data into a toxicity index for
each substance. This method covers key event 1 (in terms of protein
reactivity) and 2 (in terms of keratinocyte activation) in the skin
sensitisation AOP.
2.1.4.3. Genomic allergen rapid detection assay (GARD assay, Lund
University)
The GARD assay uses proliferating MUTZ-3 cells (a human mye-
loid leukemia-derived cell line) to measure gene expression
induced by test substances. In this cell type, a biomarker signature
was identiﬁed by analysing the transcriptional proﬁles of imma-
ture cells challenged with a panel of 38 reference substances (18
sensitisers and 20 non-sensitisers). The biomarker signature of
200 genes with the most discriminatory power to separate
between skin sensitisers and non-sensitisers was obtained by
employing an algorithm for backward elimination (Johansson
et al., 2011). To test a substance, cells are treated for 24 h with a
maximum concentration of 500 lM for highly soluble non-toxic
substances or a concentration yielding 90% viability for toxic
substances as measured with PI. Following cell stimulation, the
transcriptional levels of the 200 genes, collectively termed the
predictive biomarker signature, is evaluated using a whole genome
array (Johansson et al., 2013). Classiﬁcations of unknown
compounds as sensitisers or non-sensitisers are performed with a
support vector machine (SVM) model, trained on the 38 reference
chemicals used for GARD development, and the output is a decision
value as compared to the classiﬁcation threshold. Key event 3 is
covered with this test method.
2.1.4.4. SensiDerm™ TMT-SRM 10-Plex (Proteomics)
SensiDerm™ aims to discriminate sensitisers and non-sensitis-
ers based on pathway-speciﬁc biomarker proteins induced in the
MUTZ-3 cell line. The biomarker panel comprises the following
ten proteins which have been shown to be differentially expressed
in MUTZ-3 cells in response to sensitisers compared to non-sensi-
tisers during the assay development: glucose-6-phosphate-1-
dehydrogenase, 6-phosphoglucote dehydrogenase, heat shock pro-
tein A8, myeloperoxidase (light/heavy chain), S100A4 protein,
S100A8 protein, S100A9 protein, 4F2 cell surface antigen heavy
chain, superoxide dismutase, thymosin beta-4-like protein.
Table 1
Evaluation criteria.
General
points
Does the method address hazard (S/NS), GHS classiﬁcation
(1A, 1B, NS) or risk assessment (potency)?
Is it clear what AOP step or key event the method is
aiming to predict? (i.e. mechanistic relevance of method)
Description of test system (how close to in vivo situation)
Evidence-based approach (mechanisms) versus unspeciﬁc
biomarker
SOP/PM Is a SOP available?
Is a prediction model available?
How many chemicals have been used to deﬁne the PM?
Do the methods provide dose response information?
Data How many data are available with additional chemicals apart
from the 10 common ones?
Sensitivity
Speciﬁcity
Overall concordance
For how many of the 10 chemicals could a deﬁnite call not be
provided?
Ease of
transfer
Is the method covered by IP rights?
Has the method already been transferred to other labs? If so,
assessment of the transfer
Has the method been investigated in a pre-validation? If so,
assessment the prevalidation
Is it available at a CRO?
Throughput How many chemicals can be subjected to one experiment?
How much time is needed for one experiment (not considering
concentration-range ﬁnding)?
How many valid experiments are needed for a call?
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bility) of the test substance for 24 h with a maximum concentra-
tion of 100 lg/mL. The cellular proteins are then extracted and
analysed by mass spectrometry procedure based on selective reac-
tion monitoring. The results of the tests are provided as a ratio of
protein expression between the exposed cells and cells grown in
a control medium, which is then subjected to a polynomial model
that provides a score with a threshold to discriminate sensitisers
from non-sensitisers (Thierse et al., 2011). This method addresses
key event 3 in the skin sensitisation AOP.
2.2. Method evaluation
2.2.1. Testing of ten substances
In order to obtain a common data set for all test methods, ten
substances were selected (see Table 2 for identities). The chemicals
were purchased from Sigma–Aldrich with at least 95% purity, with
the exception of Lactic acid (approx. 90%), then coded and distrib-
uted to the test method developers by Cosmetics Europe. They
comprised three non-sensitisers including SLS, which is positive
in the LLNA, and seven sensitisers covering all sensitiser potency
classes as deﬁned by the LLNA (1 weak, 3 moderate, 2 strong, 1
extreme) including the poorly water-soluble lauryl gallate as a spe-
ciﬁcally challenging substance. Test methods developed by mem-
ber companies of Cosmetics Europe (i.e. DPRA, h-CLAT, MUSST
and PBMDC) provided existing data on these ten substances from
non-blinded testing, if available. Cosmetics Europe collected, de-
coded and evaluated the respective results. As a minimum, test
developers were asked to complete a checklist including the results
but also e.g. information on timing or protocol adherence. If pro-
vided or available, further supplementary information including
the test protocol, publications or raw test data were collected.
2.2.2. Evaluation process and criteria
Information on 15 of the 16 test methods was compiled system-
atically to enable evaluation on the basis of criteria that were
deﬁned by the Cosmetics Europe Skin Sensitisation Task Force.
The PPRA is not included in this compilation because its standardi-
sation was ﬁnalised only after evaluation had commenced. Twenty
evaluation criteria addressing various aspects of interest were
considered. For clarity, these were grouped under the headings
‘General points’, ‘Standard Operation Procedure (SOP) and predic-
tion model’, ‘data’, ‘ease of transfer’ and ‘throughput’ (Table 1).
Each test method was also mapped onto the skin sensitisation
AOP (Fig. 1).
2.2.3. Data analysis and method evaluation
The data analysis focused on the test results for the ten sub-
stances. These were available for all 16 methods. The completeness
of results and their concordance with the pre-deﬁned reference
results based on LLNA EC3 values (and human data for SLS) was
evaluated. If data on other substances were available, overall sen-
sitivity, speciﬁcity and concordance were calculated. For the 15
test methods differentiating non-sensitising and sensitising sub-
stances, the reference results were derived from both LLNA EC3
values distinguishing ﬁve potency categories and in parallel from
human data using six classes (Basketter et al., 2014). Both result
in the same potential, for nine substances (no EC3 value: non-
sensitiser; EC3 value: sensitiser; human potency classes 5 and 6:
non-sensitiser; human potency classes 1–4: sensitiser). As SLS is
false positive in the LLNA compared to human, it was considered
as a non-sensitiser. The seven test methods attempting to predict
skin sensitisation potency results used method-speciﬁc potency
categories that did not necessarily correspond to those of the
reference results. Therefore, the potency prediction results are
described only, without detailed predictivity analysis.The focus of the method evaluation exercise was to establish a
harmonised knowledge base for each of the test methods in order
to prioritise methods for further consideration. This evaluation was
carried out in close collaboration with the test method developers,
whose review concluded the evaluation process. The method
developers were invited to a two-day workshop with the Cosmet-
ics Europe Skin Tolerance Task Force held in Brussels on December
3rd and 4th 2012 to discuss their methods and results, the require-
ments of the cosmetics industry and the strategy of the task force
to meet these needs. It should be noted that the data presented
here basically reﬂect the development status of the methods as
presented at the workshop. For some methods discussions were
extended into early 2013.3. Results
3.1. Common set of ten substances
3.1.1. Skin sensitisation potential
Fifteen of the evaluated methods reported skin sensitisation
potential predictions for the ten substances. These predictions
are summarised in a harmonised way as non-sensitiser (NS) and
sensitiser (S) (Table 2) alongside the reference results. While all
ten substances were tested in all methods, for one method (Sensi-
Derm) inconclusive data were reported because timing constraints
did not allow completion of the necessary repeat experiments to
reach a ﬁnal prediction. With one exception, all test methods mis-
classiﬁed a maximum of two substances. The three sensitisers 4-
nitrobenzylbromide, cinnamal and tetramethyl thiuram disulphide
were correctly identiﬁed by all test methods, whereas the sensitis-
ers methyldibromoglutaronitrile, 2-mercaptobenzothiazole and
lauryl gallate (selected as challenging due to its poor water
solubility), were not classiﬁed in up to two test methods. Most
challenging was phenyl benzoate, which was misclassiﬁed as a
non-sensitiser by six test methods. Of the three non-sensitisers,
salicylic acid and lactic acid were mis-classiﬁed as sensitising by
one test method each, while SLS, which is false positive in LLNA
Table 2
Hazard classiﬁcation by 15 test methods for the ten chemical set. The EE potency assay is not reported here, as this method provided only potency.
Test substance CAS number Reference
result:
potential
AREc32 DPRA GARD h-CLAT Keratino-
Sens™
Lu-Sens mMUSST MUSST NCTC2544 PBMDC PPRAd SenCeeTox SensiDerm Sens-IS VITO-SENS
2-Mercaptobenzothiazole 149-30-4 Sa NS S S S S S S S NS S S S - S S
4-Nitrobenzylbromide 100-11-8 Sb S S S S S S S S S S S S S S S
Cinnamal 104-55-2 Sa S S S S S S S S S S S S - S S
Lactic acid 50-21-5 NSa NS NS NS NS NS NS NS NS S NS NS NS NS NS NS
Lauryl gallate 1166-52-5 Sa S S S S S NS S S S S S S - S S
Methyldibromoglutaronitrile 35691-65-7 Sa S S S S S S S S NS NS S S S S S
Phenyl benzoate 93-99-2 Sa S S NS S NS NS S S NS NS NS S - S NS
Salicylic acid 69-72-7 NSa NS NS NS S NS NS NS NS NS NS NS NS NS NS NS
Sodium lauryl sulphate 151-21-3 NSa,c S NS NS NS NS NS S NS NS NS NS S NS NS NS
Tetramethyl thiuram disulphide 137-26-8 Sa S S S S S S S S S S Insoluble S S S S
Concordance 8/10 10/10 9/10 9/10 9/10 8/10 9/10 10/10 6/10 8/10 8/9 9/10 6/6 10/10 9/10
NS: non-sensitiser; S: Sensitiser; -: inconclusive.
a Basketter et al. (2014).
b Gerberick et al. (2005).
Table 3
Potency classiﬁcation for the ten substance set by each of seven test methods which predict sensitiser potency.
Test substance CAS number Reference results DPRA EE KeratinoSens™ PPRA SenCeeTox Sens-IS VITOSENS
Potency based
on LLNA)
Human
potency
classa
2-Mercaptobenzothiazole 149-30-4 Moderatea 3 High na (MTT interference) Weak/moderate Reactive Moderate Moderate Moderate
4-Nitrobenzylbromide 100-11-8 Extremeb na High Extreme Strong/extreme Highly reactive Strong Extreme Extreme
Cinnamal 104-55-2 Moderatea 2 High Strong Moderate Reactive Moderate Strong Moderate
Lactic acid 50-21-5 NSa 6 Minimal Not tested NS Minimally reactive NS NS NS
Lauryl gallate 1166-52-5 Stronga 2 high na (MTT interference) strong/extreme highly reactive NS-weak moderate strong
Methyldibromoglutaronitrile 35691-65-7 Stronga 2 High Strong Strong/extreme Highly reactive Strong-extreme Strong Strong
Phenyl benzoate 93-99-2 Weaka 3 Moderate Very weak/NS NS Minimally reactive NS-weak Weak NS
Salicylic acid 69-72-7 NSa 6 Minimal Not tested NS Minimally reactive NS-weak NS NS
Sodium lauryl sulphate (SLS) 151-21-3 NSa,c 6 Minimal Not tested NS Minimally reactive Weak NS NS
Tetramethyl thiuram disulphide 137-26-8 Moderatea 3 High na (solubility) Strong/extreme na (solubility) Moderate Moderate Extreme
NS: non-sensitiser; na: not available.
a Basketter et al. (2014).
b Gerberick et al. (2005).
c False positive in the LLNA, thus considered as non sensitiser.
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tising by three test methods. Interestingly, some differences in pre-
diction were found with similar test methods. The three ARE cell
line assays (KeratinoSens™, LuSens, AREc32) showed concordant
results for only six of the ten substances. This was also the case
for the test methods based on dendritic cell surrogates (h-CLAT,
MUSST, mMUSST, PBMDC), which came to the same conclusion
for six substances only. The reasons for these differences remain
to be discussed, but are most likely due to differences in the test
method protocols such as cells or prediction models used.
3.1.2. Skin sensitisation potency
Of the seven test methods predicting skin sensitiser potency, six
do not require prior classiﬁcation of a chemical as sensitising, but
the EE potency assay does. Therefore the three non-sensitisers
were not tested in this assay. Potency categories are not deﬁned
consistently across different test methods. Sens-IS, VITOSENS and
the EE potency assay apply the ﬁve LLNA categories from non-
sensitiser to extreme, whilst KeratinoSens™ and SenCeeTox in
addition allow assignment of substance to intermediate categories
such as non-weak or strong/extreme. In contrast, DPRA categorises
chemical reactivity with peptides as minimal, low, moderate or
high, and the PPRA as minimally reactive, reactive or highly reac-
tive. Table 3 summarises the potency predictions of all seven
methods together with the reference results as derived from the
LLNA and in terms of human potency categories as reported in
Basketter et al. (2014).
The EE potency assay only assesses known sensitisers for their
sensitising potency and was susceptible to reduction of cell viabil-
ity (as shown by MTT staining) or solubility problems for three
substances. Therefore test results for only four of the seven sensi-
tisers were available (non sensitisers were not tested). The PPRA
encountered solubility issues with tetramethyl thiuram disulphide,
but test results were obtained for the remaining nine chemicals.
Potency predictions for all ten chemicals were obtained from the
other ﬁve test methods. With the exception of the strong sensitiser
lauryl gallate being predicted as ‘NS-weak’ in SenCeeTox, potency
predictions were either correct or differed to the reference result
by only one category in all cases for Sens-IS, KeratinoSens™, Vito-
Sens and SenCeeTox. No bias towards under- or over-prediction of
potency was observed.
The DPRA and the PPRA use fewer potency categories than the
LLNA. The six substances with LLNA reference results of moderate,
strong and extreme were all classiﬁed by the DPRA as having ‘high’
reactivity, phenyl benzoate (classiﬁed as weak by the LLNA) as
‘moderate’ and the three non-sensitisers as ‘minimal’. The PPRA
classiﬁed LLNA extreme and strong sensitisers as highly reactive,
the LLNA moderate sensitisers as reactive, and the LLNA weak
and non-sensitisers as minimally reactive.
Human skin sensitisation data are available for six of the seven
sensitising substances, which were all assigned as human potency
class ‘2’ and ‘3’ (Basketter et al., 2014). This correlated well with
their classiﬁcation based on LLNA results – which ranged from
weak to strong – with only minor differences for cinnamal and
phenyl benzoate. Consequently, the potency prediction from the
test methods broadly matched the human potency classes in a sim-
ilar manner as described above for the LLNA.
At the time of the workshop the h-CLAT had already been pro-
posed for potency predictions (Nukada et al., 2012), but it was not
proposed by the test developer for this application at the time of
evaluation.
3.1.3. Method evaluation according to the pre-deﬁned criteria
The evaluation of all test methods, except the PPRA (because
method standardisation was ﬁnalised only after evaluation had
commenced), was performed according to the criteria detailedabove and is presented in Table 4. In summary, the methods were
characterised by the test system (cell line – 9 methods; 3D tissue –
3; primary cells – 2; synthetic peptide – 1) and the number of skin
sensitisation biomarkers (speciﬁc or non-speciﬁc) measured.
Regarding conduct of the methods and the data analysis, SOP and
prediction models were – unless they were considered as conﬁden-
tial – provided by the test developers. As an indicator of the robust-
ness of the prediction model, the number of chemicals used to
develop the model was also captured. For most methods prediction
models were based on more than 25 substances, which was con-
sidered as sufﬁcient. Similarly, the number of test concentrations
used was considered as an indicator for the potential generation
of concentration–response data. Whilst three test methods use
fewer than four concentrations (which is unlikely to allow investi-
gation of concentration–responses), the ﬁve test methods which
involve more than six test concentrations are likely to be able to
provide this type of information.
The number of substances tested – in addition to the ten test
substance set – for which data and/or predictions were available
for each method, was captured. This number was smaller than 10
for three test methods. More than 40 substances had been tested
in the remaining methods, for which the predictive performance
in terms of speciﬁcity, sensitivity and concordance with the skin
sensitisation potential as determined by the LLNA was calculated.
While both sensitivity and speciﬁcity ranged from approximately
65% to 100%, the concordance was at least 73%. As many factors,
especially the identity and number of substances tested, may have
a signiﬁcant impact on these performance parameters, they should
be considered with care as they therefore do not lend themselves
necessary for comparison.
Information on transferability and throughput that were used to
characterise practical aspects of testing were of particular interest
to our evaluation. Intellectual property rights protected about half
of the methods. While locally restricted rights – as in the case of
the h-CLAT – were of little concern, rights constituting an obstacle
to wide and non-exclusive availability of methods were of higher
concern. Aspects such as previously successful method transfer,
pre-validation activities and the availability of test methods at
CROs were of interest in this regard. It was found that most meth-
ods had already been transferred or a transfer was planned or ongo-
ing. Likewise, mostmethods are available at a CRO. Obviously, more
established methods, such as the DPRA, KeratinoSens™, PBMDC,
MUSST or h-CLAT are more likely to have undergone a validation
exercise establishing their transferability and reproducibility.
Regarding the throughput, most methods can test at least six
substances in parallel in one experiment. However, the duration
and minimum number of required valid experiments may differ
considerably. As a consequence, the average time to test a sub-
stance may be a short as one week (for example in the DPRA), or
also as long as three to four weeks (using VITOSENS).
Based on the information collected, test methods were priori-
tised based on voting by the Cosmetics Europe member companies
represented in the Skin Tolerance Task Force for further evaluation
in a more detailed second evaluation phase. For initial data integra-
tion exercises, test methods were chosen, for which substantial
information was available. Protocol robustness, proven transfer-
ability and reproducibility – generally demonstrated by successful
multi-laboratory studies – apparently were important test meth-
ods characteristics considered in this process, together with
amount of existing data and availability through contract research
organisations. The voting resulted in the selection of the DPRA,
KeratinoSens™, MUSST and h-CLAT for further evaluation. These
methods primarily focus on prediction of hazard potential. There-
fore methods that were considered to show potential for prediction
of skin sensitisation potency and that use gene regulation or pro-
teomics as biomarkers (GARD, SensiDerm™, Sens-IS, SenCeeTox
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bl
e
4
Reisinger and Hoffmann et al. / Toxicology in Vitro 29 (2015) 259–270 267
268 Reisinger and Hoffmann et al. / Toxicology in Vitro 29 (2015) 259–270and VITOSENS) were also selected. In addition, the PPRA as a
potential improvement of the DPRA was prioritised.
4. Discussion
Cosmetic Europe’s Skin Tolerance Task Force is developing a
data integration approach for the skin sensitisation safety assess-
ment of cosmetic ingredients. This requires a non-animal testing
strategy, which delivers skin sensitisation potency predictions. It
is of utmost importance that the strategy is developed in a way
that ensures all stakeholders will have a high level of conﬁdence
in the produced results. Conﬁdence will be built by (a) incorporat-
ing current mechanistic understanding – guided by the OECD AOP,
(b) the amount and quality of data used in strategy construction,
(c) transparent and objective strategy composition (Jaworska and
Hoffmann, 2010) and (d) satisfactory predictive performance. It
will need to offer ﬂexibility to adjust to speciﬁc purposes, e.g. for
cases requiring only hazard identiﬁcation not potency estimation,
and demands (including applicability domain issues). Therefore,
we envisage that the term ‘strategy’ is used here to collectively
describe an array of testing and data integration approaches. It is
planned that a default or standard strategy for potency prediction
will be developed, that is intended for cases without any relevant a
priori information on the substance to be tested. In other cases
where a priori information exists, or the purpose is not potency
estimation, modiﬁcations to this default and/or speciﬁcally tailored
strategies will be available. A-priori information may include
(i) physico-chemical properties, including molecular weight,
the octanol–water partition coefﬁcient and physical form
at room temperature,
(ii) potency expectation such as derived by read-across or
Q(SAR) approaches,
(iii) intended function (e.g. dye) or origin (e.g. natural extracts),
(iv) information on suspected transformation – whether activa-
tion or deactivation by oxidation or metabolic processes
(e.g. for pre- or pro-haptens),
(v) skin penetration from data or expectations based on model-
ling approaches,
(vi) available in vitro test method data (where insufﬁcient for
concluding on potency).
As examples, approaches to conﬁrm the expectation of a
substance being a non-sensitiser or approaches specially suited
for lipophilic substances (which may be difﬁcult to test in an
aqueous, cell line based assay) are likely to be required.
The testing strategy is expected to provide an ordinal resolution
of the potency spectrum preferably distinguishing ﬁve categories
(non, weak, moderate, strong, extreme). The references for assess-
ing the strategy’s performance will be human (six categories) as
proposed by Basketter et al. (2014) and LLNA (EC3, categorised in
5 classes) data. EC3 values will be harvested from existing publica-
tions and qualify for inclusion only if certain criteria, including the
speciﬁcation of the vehicle, test concentrations and stimulation
indices, are fulﬁlled. Variability associated with replicate EC3
values will be taken into account.
To reach this aim of developing a non-animal testing strategy
for potency prediction, three phases frame our efforts (Fig. 2).
The outcome of the ﬁrst of these phases, the evaluation of existing
test methods supporting prioritisation for further consideration is
presented here. Sixteen test methods with data in common for a
set of 10 substances were considered during this evaluation. With
the exception of test methods developed by member companies of
Cosmetics Europe (i.e. DPRA, h-CLAT, MUSST and PBMDC) that
provided existing data from non-blinded testing, coded substances
were tested. However, for calculation of the predictivity of mostmethods including these four, available data on additional chemi-
cals were considered (in most cases P40 substances, Table 4), so
that potential impact of coded versus non-coded testing on predic-
tivity become marginal. With the cooperation of the test method
developers, additional information relevant to a pre-deﬁned list
of criteria that addressed a number of parameters including the
level of standardisation, existing test data, potential for through-
put, transferability and accessibility was systematically collated.
The outcome of this evaluation was reviewed by each test method
developer, discussed at a workshop held with the method develop-
ers, and ultimately informed the prioritisation of test methods for
phase II of the evaluation process.
Initially, the ten test methods DPRA, GARD, h-CLAT,
KeratinoSens™, MUSST, PPRA, SenCeeTox, SensiDerm, Sens-IS and
VITOSENS were prioritised based on voting by the Cosmetics
Europe member companies represented in the Skin Tolerance Task
Force. At a later stage, one test method was dropped because sig-
niﬁcant optimisation would be needed, while another was stopped
due to organisational issues. During phases II and III of the Cosmet-
ics Europe framework new developments of existing or up-coming
methods such as the efforts by Teunis et al. (2013, 2014), or van der
Veen et al. (2015), will be monitored and considered in case they
can be expected to improve the testing strategy.
The basis for the testing strategy composition will be more than
100 substances, for which both LLNA and human data are available.
It is planned that test results from all eight phase II methods for all
substance will be available. For each test method the data consid-
ered most useful for the testing strategy composition will be
deﬁned. This implies that the potential contribution of read-out
parameters – instead of currently applied prediction models – to
the strategy will be explored, especially for the methods that on
hazard assessment. For example, for the DPRA relative cysteine
and lysine depletion will be used. It has to be noted that properties
of the data of the various methods differ. While the methods of ﬁrst
priority have a few relevant read-outs to be captured, this will be
more complex for other methods, such as Sens-IS or GARD that
measure an array of genes. Variability of the methods will be
accounted for. While for methods that have undergone a validation
exercise, the usually derived information on within- and between-
laboratory reproducibility is readily available, this will be less
straightforward at least for some of the other methods. As a
substantial number of the substances have already been tested
for some of the methods, it is expected that the remaining data
gaps will be ﬁlled soon. This will allow re-assessment of already
proposed testing strategies, e.g. by Bauch et al. (2012), Gomes
et al. (2012), Nukada et al. (2012), Natsch et al. (2013) or
Jaworska et al. (2013), with new data. Once the data for the eight
test methods will be available, a testing strategy will be composed
addressing the speciﬁc purposes and needs as described above.
Driven by the mechanistic understanding and supported by data
analysis specialists, data mining and other statistical tools will be
used to combine test method data in an objective and transparent
way to obtain a predictive testing strategy that will be made
publicly available. Predictive performance will be assessed correl-
atively/probabilistically against the reference human and LLNA
data or a combination thereof. Although efﬁciency and other fac-
tors, such as availability or duration, may – at least at this stage
– not be accounted for, it is nevertheless expected that the strategy
will comprise a limited number of test methods.
In the third phase of the framework, applicability domain issues
speciﬁcally relevant for substance used by cosmetic industry will
be addressed. It is anticipated that for inherently problematic sub-
stance types, such as natural extracts, dyes or polymers, further
data may be required in order to provide sufﬁcient evidence that
the testing strategy works for these substance types or to optimise
the adaptation of the strategy.
Phase I 
METHOD 
PRIORITISATION
Phase II 
TESTING 
STRATEGY 
DEVELOPMENT
Phase III
APPLICABILITY 
DOMAIN 
ANALYSIS
Evaluaon
- Data on 10 common coded substances 
- Informaon gathered on evaluaon criteria
16 test methods
Priorised methods
- DPRA   - GARD 
- h-CLAT   - KeranoSensTM
- MUSST   - PPRA   
- Sens-IS   - VITOSENS
Non-priorised methods
parcipaon on  
own iniave
-
Tesng strategy composion
- Generate data for 100+ substances with LLNA and human data 
- Evaluate test method inter-dependencies 
- Construct tesng strategy 
TESTING STRATEGY
Default:  
- hazard idenﬁcaon,  
incl. according to CLP/GHS 
- potency 
Potenal addional requirements: 
- conﬁrm non-sensiser 
- lipophilic substance 
Tesng of challenging cosmec substances
Focused tesng  to explore applicability domains of  
the priorised test methods to opmise  
the tesng strategy
Fig. 2. Cosmetics Europe’s three-phase framework for development of a non-animal testing strategy for skin sensitisation potency prediction (CLP: Classiﬁcation, Labelling
and Packaging; GHS: Globally Harmonised System). In phase I 16 non-animal test methods were evaluated based on predeﬁned criteria detailed in Table 1. In phase II an
extensive database will be generated comprising more than 100 chemicals, for which human data and LLNA EC3 values are available. This resulting data set will used to
develop a test strategy for predicting hazard identiﬁcation and characterisation (potency) with non-animal test methods only. In phase III the test strategy will be optimised
after challenging the prioritized methods with compounds of speciﬁc interest for cosmetic industry (e.g. UV-ﬁlters, preservatives, hair dyes).
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potency predictions will be combined with bioavailability and skin
metabolism data, exposure consideration and in exceptional cases
with data from T cell activation assays, to satisfy the ultimate goal
of a data integration approach for skin sensitisation safety assess-
ment of cosmetic ingredients.
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